Low-dose suramin enhanced paclitaxel activity in chemotherapy-naïve and paclitaxel-pretreated human breast xenograft tumors

Clinical Cancer Research

Volumn 10, Issue 18 I, 2004, Pages 6058-6065

  Song, SaeHeum ^a   Yu, Bei ^a   Wei, Yong ^a   Wientjes, M Guillaume ^a,b   Au, Jessie L S ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; PACLITAXEL; SURAMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL STRAIN MCF 7; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TOXICITY; FEMALE; HUMAN; HUMAN CELL; LOW DRUG DOSE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BODY WEIGHT; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE PROGRESSION; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PACLITAXEL; SURAMIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 4644265735     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0595     Document Type: Article

References (53)

1. Song S, Wientjes MG, Gan Y, Au JL. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA 2000;97:8658-63.
2. Coffey RJ Jr, Goustin AS, Soderquist AM, et al. Transforming growth factor alpha and beta expression in human colon cancer lines: implications for an autocrine model. Cancer Res 1987;47:4590-4.
3. Pollak M, Richard M. Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells. J Natl Cancer Inst (Bethesda) 1990;82:1349-52.
4. Williams LT, Tremble PM, Lavin MF, Sunday ME. Platelet-derived growth factor receptors form a high affinity state in membrane preparations. Kinetics and affinity cross-linking studies. J Biol Chem 1984;259:5287-94.
5. Hosang M. Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem 1985;29:265-73.
6. Garrett JS, Coughlin SR, Niman HL, Tremble PM, Giels GM, Williams LT. Blockade of autocrine stimulation in simian sarcoma virus-transformed cells reverses down-regulation of platelet-derived growth factor receptors. Proc Natl Acad Sci USA 1984;81:7466-70.
7. Betsholtz C, Johnsson A, Heldin CH, Westermark B. Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin. Proc Natl Acad Sci USA 1986;83:6440-4.
8. Myers CE, LaRocca R, Stein C, et al. Treatment of hormonally refractory prostate cancer with suramin [abstract]. Proc Am Soc Clin Oncol 1990;9:54.
9. Song S, Wientjes MG, Walsh C, Au JL. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases. Cancer Res 2001;61:6145-50.
10. Zhang Y, Song S, Yang F, Au JL, Wientjes MG. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. J Pharmacol Exp Ther 2001;299:426-33.
11. Yu B, Song S, Wientjes MG, Au JL. Suramin enhances activity of CPT-11 in human colorectal xenograft tumors [abstract]. Proc Am Assoc Cancer Res 2003;44:174.
12. Ogden A, Song S, Wientjes MG, Au JL. Nontoxic doses of suramin enhance the activity of gemcitabine and paclitaxel in pancreatic tumors [abstract]. Proc Am Assoc Cancer Res 2004;45:494.
13. Xin Y, Chen D, Song S, Lyness G, Wientjes MG, Au JL. Low-dose suramin enhances antitumor activity of mitomycin C in bladder tumors [abstract]. Proc Am Assoc Cancer Res 2004;45:461.
14. Lyness G, Jang S, Can Y, Zhang Y, Wientjes MG, Au JL. Fibroblast growth factors and chemoresistance in renal cell carcinomas [abstract]. Proc Am Assoc Cancer Res 2002;43:953.
15. Villalona-Calero MA, Wientjes MG, Otterson GA, et al. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. Clin Cancer Res 2003;9:3303-11.
16. Villalona-Calero MA, Otterson GA, Wientjes MG, et al. Phase II evaluation of low dose suramin as a modulator of paclitaxel/carboplatin (P/C) In non-small cell lung cancer (NSCLC) patients. Lung Cancer 2003;41(Suppl 2):149.
17. Ruotsalainen TM, Mattson K. Interferon trials in small cell lung cancer at one institution: a comparison of results obtained before and after initiation of systematic treatment trials using IFN-alpha in combination with other modalities. J Interferon Cytokine Res 2002;22:165-71.
18. Miyake H, Hara I, Gohji K, Yoshimura K, Arakawa S, Kamidono S. Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line. Cancer Lett 1998;123:121-6.
19. Menzel T, Rahman Z, Calleja E, et al. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 1996;87:1056-63.
20. Fuks Z, Persaud RS, Alfieri A, et al. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res 1994;54:2582-90.
21. Dini G, Funghini S, Witort E. et al. Overexpression of the 18 kDa and 22/24 kDa FGF-2 isoforms results in differential drug resistance and amplification potential. J Cell Physiol 2002;193:64-72.
22. Carroll SM, Carroll CM, Stremel RW, et al. Vascular delay and administration of basic fibroblast growth factor augment latissimus dorsi muscle flap perfusion and function. Plast Reconstr Surg 2000;105:964-71.
23. Brill G, Vaisman N, Neufeld G, Kalcheim C. BHK-21-derived cell lines that produce basic fibroblast growth factor, but not parental BHK-21 cells, initiate neuronal differentiation of neural crest progenitors. Development (Camb) 1992;115:1059-69.
24. Wang H, Rubin M, Fenig E. et al. Basic fibroblast growth factor causes growth arrest in MCF-7 human breast cancer cells while inducing both mitogenic and inhibitory G1 events. Cancer Res 1997;57:1750-7.
25. Wang Q, Maloof P, Wang H, et al. Basic fibroblast growth factor downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells. Exp Cell Res 1998;238:177-87.
26. Maloof P, Wang Q, Wang H, et al. Overexpression of basic fibroblast growth factor (FGF-2) downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells. Breast Cancer Res Treat 1999;56:153-67.
27. Coleman AB, Metz MZ, Donohue CA, Schwarz RE, Kane SE. Chemosensitization by fibroblast growth factor-2 is not dependent upon proliferation, S-phase accumulation, or p53 status. Biochem Pharmacol 2002;64:1111-23.
28. Fenig E, Wieder R, Paglin S, et al. Basic fibroblast growth factor confers growth inhibition and mitogen-activated protein kinase activation in human breast cancer cells. Clin Cancer Res 1997;3:135-42.
29. Yiangou C, Gomm JJ, Coope RC, et al. Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance. Br J Cancer 1997;75:28-33.
30. Colomer R, Aparicio J, Montera S, Guzman C, Larrodera L, Cortes-Funes H. Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. Br J Cancer 1997;76:1215-20.
31. Eppenberger U, Kueng W, Schlaeppi JM, et al. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 1998;16:3129-36.
32. Faridi A, Rudlowski C, Biesterfeld S, Schuh S, Rath W, Schroder W. Long-term follow-up and prognostic significance of angiogenic basic fibroblast growth factor (bFGF) expression in patients with breast cancer. Pathol Res Pract 2002;198:1-5.
33. Visscher DW, DeMattia F, Ottosen S, Sarkar FH, Crissman JD. Biologic and clinical significance of basic fibroblast growth factor immunostaining in breast carcinoma. Mod Pathol 1995;8:665-70.
34. Au JL, Li D, Gan Y, et al. Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. Cancer Res 1998;58:2141-8.
35. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (Bethesda) 2000;92:205-16.
36. Gan Y, Wientjes MG, Schuller DE, Au JL. Pharmacodynamics of Taxol in human head and neck tumors. Cancer Res 1996;56:2086-93.
37. Gold R, Schmied M, Giegerich G, et al. Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Investig 1994;71:219-25.
38. Koelling TM, Yeager AM, Hilton J, Haynie DT, Wiley JM. Development and characterization of a cyclophosphamide-resistant subline of acute myeloid leukemia in the Lewis X Brown Norway hybrid rat. Blood 1990;76:1209-13.
39. Caffrey PB, Zhange Y, Frenkel GD. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in vivo. Anticancer Res 1998;18:3021-6.
40. Stein CA, LaRocca RV, Thomas R, McAtee N, Myers CE. Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 1989;7:499-508.
41. Dreicer R, Smith DC, Williams RD, See WA. Phase 11 trial of suramin in patients with metastatic renal cell carcinoma. Investig New Drugs 1999;17:183-6.
42. Falcone A, Pfanner E, Brunetti I, et al. Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU + LV-based chemotherapy. Tumori 1998;84:666-8.
43. Falcone A, Antonuzzo A, Danesi R, et al. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. Cancer (Phila) 1999;86:470-6.
44. Hussain M, Fisher EI, Petrylak DP. et al. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: a Southwest Oncology Group Study. J Clin Oncol 2000;18:1043-9.
45. Miglietta L, Canobbio L, Granetto C, Vannozzi MO, Esposito M, Boccardo F. Suramin/epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase 11 study. J Cancer Res Clin Oncol 1997;123:407-10.
46. Mirza MR, Jakobsen E, Pfeiffer P, Lindebjerg-Clasen B, Bergh J, Rose C. Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase 11 studies. Acta Oncol 1997;36:171-4.
47. Motzer RJ, Dmitrovsky E, Miller WH, et al. Suramin for germ cell tumors. In vitro growth inhibition and results of a phase 11 trial. Cancer (Phila) 1993;72:3313-7.
48. Rapoport BL, Falkson G, Raats JI, de Wet M, Lotz BP, Potgieter HC. Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase 11 clinical study. Ann Oncol 1993;4:567-73.
49. Reyno LM, Egorin MJ, Eisenberger MA, Sinibaldi VJ, Zuhowski EG, Sridhara R. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. J Clin Oncol 1995;13:2187-95.
50. Rosen PJ, Mendoza EF, Landaw EM, et al. Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. J Clin Oncol 1996;14:1626-36.
51. Qiao L, Pizzolo JG, Melamed MR. Effects of suramin on expression of proliferation associated nuclear antigens in DU-145 prostate carcinoma cells. Biochem Biophys Res Commun 1994;201:581-8.
52. Howard SP, Park SJ, Hughes-Davies L, Coleman CN, Price BD. Suramin increases p53 protein levels but does not activate the p53-dependent G1 checkpoint. Clin Cancer Res 1996;2:269-76.
53. Palayoor ST, Bump EA, Teicher BA, Coleman CN. Apoptosis and clonogenic cell death in PC3 human prostate cancer cells after treatment with gamma radiation and suramin. Radiat Res 1997;148:105-14.